In recent years, a novel biologic therapy with monoclonal antibodies against tumor necrosis factor-alpha has revolutionized the treatment of Crohn's disease. Infliximab, the first biologic agent, has been demonstrated to considerably improve both clinical and endoscopic outcomes. In view of the growing popularity of infliximab in the management of Crohn's disease, we review the profile of the agent in the treatment of this disease in a pediatric setting.
CITATION STYLE
Kierkus, J., Szymanska, E., Oracz, G., Wiernicka, A., & Dadalski, M. (2015). Profile of infliximab in the treatment of pediatric Crohn’s disease. Pediatric Health, Medicine and Therapeutics, 79. https://doi.org/10.2147/phmt.s64943
Mendeley helps you to discover research relevant for your work.